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The mumps virus is a single-stranded, non-segmented, negative-
sense RNA virus belonging to the Paramyxoviridae family. Mumps 
is characterized by bilateral or unilateral swelling of the parotid 
gland. Aseptic meningitis is a common complication, and orchitis 
is also common in adolescents and adult men. Diagnosis is based 
on clinical findings, but because of high vaccination coverage, 
clinical findings alone are not sufficient for diagnosis, and laboratory 
confirmation is needed. Mumps is preventable by vaccination, 
but despite high vaccination coverage, epidemics occur in several 
countries, including Korea. Many hypotheses are suggested for 
these phenomena. In this review, we investigate the reason for 
the epidemics, optimal methods of diagnosis, and surveillance of 
immunization status for the prevention of future epidemics.
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with low vaccination coverage, but currently because of high 
vaccine coverage and low incidence of mumps, clinical diagnosis of 
mumps is complicated. Major outbreaks have occurred worldwide, 
despite the high rate of vaccination coverage
2-5). The incidence of 
mumps is on the rise in Korea, as reported by the Korea Centers 
for Disease Control and Prevention (KCDC) (Fig. 1). Various 
hypotheses have been suggested as the cause for the increase in 
mumps. The current status quo of mumps infections in Korea is 
described and potential preventive measures are suggested along 
with a review of the literature. 
Virology
The mumps virus is a single-stranded, non-segmented, negative-
sense RNA virus that belongs to the Paramyxoviridae family 
along with parainfluenza virus, measles virus, respiratory syncytial 
virus, and human metapneumovirus. It is composed of 7 major 
Introduction
The history of mumps dates back to the 5th century B.C., when 
Hippocrates described it as “bilateral or unilateral swelling near 
the ears, and some of them had bilateral or unilateral pain and 
swelling of the testicles.”. However, isolation and culture of the 
virus was only possible in 1945, and vaccination was first licensed 
in 1967. Without routine immunization, the incidence is estimated 
to be 100-1,000 cases per million, with an epidemic every 4-5 
years. However, universal vaccination has contributed greatly to 
the decline in the incidence of mumps worldwide. Finland was the 
first country to declare itself mumps-free in 2000 after a national 
2-dose MMR vaccination program for children, resulting in high 
vaccination coverage
1). In Korea, the mumps vaccine was included 
in the National Immunization Program (NIP) in 1985, and a 
booster dose was given from 1997. 
The clinical diagnosis of mumps is not difficult in population 
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and in the United States in 2006
9) were hot topics in the field of 
infectious diseases. MMR vaccination was initiated in the United 
Kingdom in 1988, followed by a booster dose in 1996. Such 
policies were helpful in decreasing the incidence of mumps to less 
than 5,000 cases in 2003. However, a sudden rise in the incidence 
of mumps was observed in 2005, with over 56,000 cases being 
reported in the United Kingdom. Most patients were 19-23 years 
of age and had only been vaccinated once. 
An outbreak in the United States was reported in 2006; over 
5,800 cases were reported. Most cases were in college students aged 
18-24 years and the majority had been vaccinated twice
16). Both 
effectiveness and uptake appear to not to have been sufficient to 
obtain herd immunity for mumps in populations such as college 
students
17). A difference in the geometric mean titers (GMTs) of 
the serum neutralizing antibody in the causative strain and the 
Jeryl-Lynn strain used in the vaccine was also observed
6). The 
epidemic occurred despite high vaccination rates and low mumps 
activity in the community
18). Reports of outbreaks are continuing, 
with an outbreak in New York and New Jersey and also in highly 
vaccinated populations between June 2009 and January 2010
19).
The outbreaks are believed to be caused by multiple factors: 
inadequate levels of vaccination, primary or secondary vaccine 
failure, antigenic differences between the outbreak and vaccine 
strains, increased risk of transmission associated with college 
campuses, inherent limitations in mumps protective immunity, 
and misdiagnosis of infection. 
Clinical manifestations
Some of the following clinical features may be found in cases of 
mumps.
1. Short course with non-specific signs and symptoms 
2. Full-blown case with swelling of salivary glands without but 
no complications
3. Severe mumps and complications
4. No apparent symptoms but typical antibody responses
5. Meningoencephalitis or orchitis but no involvement of the 
salivary glands
Approximately 75% of all cases of apparent mumps in children 
are full-blown but without complications. Up to 30% of children 
infected with mumps may not even show signs of parotitis. 
Parotid gland swelling is at its maximum at 1-3 days and gradually 
decreases by 7 days. Generally, the clinical manifestations appear 
to be mild in children and severe in adults. Complications are less 
common after vaccination. 
proteins, and the major antigens are glycoproteins V antigen and F 
protein, and a nucleocapsid protein S antigen. It is subdivided into 
12 genotypes according to the hydrophobic membrane-associated 
protein (SH), and the B, F, and I genotypes are common in Asia. 
The cross-neutralization capacity of the genotypes is known to 
have decreased but this alone does not explain the increase in 
vaccine failure
6), which needs to be addressed further. In terms 
of immunology, mumps has only 1 immunotype similar to 
the measles virus and humans are its only host. Its virulence is 
destroyed with heat and attenuated with UV light. 
Epidemiology
Prior to vaccination, mumps was an epidemic disease, with a 
cycle of 4-5 years. It was predominant in the pediatric population, 
with seasonal outbreaks in winter and spring. It had been reported 
that by adolescence, 90% of the population demonstrated serologic 
evidence of infection
7). Mumps was a well-known cause of aseptic 
meningitis and sensorineural hearing loss. The first dose of 
vaccination decreased the incidence of mumps by 88-98%, and the 
booster dose decreased the incidence by 97-99%
8). 
Sporadic outbreaks have been reported in several countries, 
including Belarus, the United States, Canada, the United 
Kingdom, Israel, Moldova, and Netherlands
3-5, 9-12). In Korea, an 
outbreak was reported between 1986 and 1991 after the NIP was 
initiated, and the outbreak was believed to have been caused by 
primary vaccine failure. Subsequent administration of a booster 
dose contributed to a decrease in the incidence of mumps. 
Currently, in Korea, the incidence of mumps is on a constant rise, 
with 1,668 cases being reported in 2001, 1,518 cases in 2003, 4,557 
cases in 2007, 4,542 cases in 2008, and 6,400 cases in 2009 (Fig. 1). 
The genotypes circulating in Korea have been identified as H and 
I
13, 14).
The recent mumps outbreaks in the United Kingdom in 2005
15) 
Fig. 1.  Reported number of mumps cases in Korean since 2001. Mumps 
cases have increased since 2001. Adapted from the Korea Centers for 
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Except for the cases with complications, a typical mumps 
infection follows the course of fever, anorexia, headache, vomiting, 
and generalized aches and pains during the prodromal periods 
of days 1 and 2. Then, the parotid gland begins to enlarge and 
the enlargement is accompanied by slight redness of the orifices 
of the Stensen or Wharton ducts; 70-80% of cases show bilateral 
involvement. 
Aseptic meningitis is the most common complication in 
children. Meningeal irritation signs are more prevalent in older 
children, adolescents, and adults, and nonspecific findings such as 
drowsiness and lethargy prevail in younger children. Further, 50-
60% of patients have pleocytosis in the cerebrospinal fluid (CSF) 
but only one-sixth of these patients have meningeal symptoms. 
Encephalitis develops in approximately 0.5% cases, and mumps 
meningoencephalitis is known to have better prognosis than other 
viral meningoencephalitis. 
Epididymo-orchitis and oophoritis does not occur if the 
infection occurs prior to adolescence. They are the most common 
clinical manifestations after parotitis in adolescent boys and adult 
men, usually in those aged 15-29 years. In 80% of all mumps 
orchitis cases, symptoms are first observed during the first 8 days of 
involvement of the salivary gland, usually unilateral involvement, 
with 15-30% of cases showing bilateral involvement
20, 21). Sterility 
may be caused by bilateral orchitis in rare cases. Oophoritis occurs 
in approximately 7% of postpubertal female patients and manifests 
as pelvic pain and tenderness. 
Pancreatitis occurs in 3% of cases
22) but rarely with severe 
involvement that causes epigastric pain and tenderness, fever, chills, 
vomiting, and prostration. A connection with diabetes mellitus is 
suspected in experimental animals, which showed hyperglycemina 
and histologic lesions of the pancreatic islets.  
Viruria is common in uncomplicated mumps cases and is 
accompanied by mild abnormalities in renal function
23); severe and 
fatal nephritis is a rare complication. 
Deafness occurs in 0.5-5.0/100,00 cases of mumps
24), but 
mild degrees of hearing impairment are thought to be more 
common. Mumps-associated deafness may occur with or without 
meningoencephalitis after asymptomatic infection, and it is usually 
unilateral and often permanent. Occasional reports of vertigo have 
been reported. 
Prior to the development of the vaccine, the incidence of mumps 
during pregnancy was 0.8-1.0 cases per 10,000 pregnancies
25). An 
increase in fetal mortality in the 1st trimester, with a spontaneous 
abortion rate of 25% was observed but no evidence of in increased 
risk for fatal malformations was found
26).
Other less frequent manifestations are exanthem and enanthem, 
arthritis, myocarditis, thrombocytopenia, keratouveitus, lower 
respiratory tract infection, and other glandular involvement 
(thyroiditis, mastitis, dacryoadenitis, and bartholinitis).
Transmission
The virus replicates within the upper respiratory tract and is 
transmitted through contaminated respiratory droplets or saliva 
and fomites. The virus is isolated 7 days before and 9 days after 
parotid gland swelling, with the greatest transmission during 
the 7-day period beginning 2 days before the onset of parotitis. 
Asymptomatic patients may also shed the virus. The incubation 
period spans from 12 days up to a maximum of 25 days and is 
usually known to be 16-18 days. Since the infectivity of mumps 
is lower than that of measles, a significant number of persons pass 
through childhood without being infected with the mumps virus.
Pathogenesis and pathology
Primary viral replication occurs in the upper respiratory mucosal 
epithelium. Then, the virus drains to the local lymph nodes. After 
that, viremia occurs, and the virus spread to multiple secondary 
infection sites, including the salivary glands, inner ear, pancreas, 
heart, nervous system, joints, kidneys, liver, gonads, and thyroid.
In response to viral infection, humoral and cellular immune 
responses are activated. The humoral immune response is induced 
by the production of serum antibodies to the V, F, and S antigens. 
The antibody to the S antigen persists for 3-7 days after the onset 
of symptoms and is short-lived; it is usually absent after 6 months. 
The antibody to the V antigen is noted for 2-4 weeks after the 
onset of illness and persists for long periods after infection. IgM is 
present early in the course of infection and is usually undetectable 
for 3 months after the onset of illness. IgG is detected at the 
end of the first week of illness; it peaks 3 weeks later and persists 
throughout life, mainly as IgG1. Salivary IgA is produced as well. 
Reinfection is common and patients with a history of mumps 
show antibody response patterns suggestive of reinfection and not 
primary infection. Specifically, the IgG but not IgM titer rises in 
these patients. The cellular immune response is also induced. In a 
study by Gans et al
27), approximately two-thirds of vaccinees who 
did not seroconvert developed T cell immunity to the mumps 
virus. Jokinen et al
28) reported very long persistence of vaccine-
induced anti-mumps virus cellular immunity. Nevertheless at 
present, it is not known whether the humoral or cellular immune 
response is more important for protective immunity to the mumps 
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Diagnosis
According to the Centers for Disease Control and Prevention 
(CDC), a clinical case of mumps is defined as acute onset of 
unilateral or bilateral tender, self-limited swelling of the parotid 
or other salivary glands that lasts for ≥2 days and occurs in the 
absence of other apparent causes. Confirmed cases are either 
laboratory confirmed or meet the clinical case definition and are 
epidemiologically linked to a confirmed or probable case. Probable 
cases meet the clinical case definition but are neither laboratory-
confirmed nor epidemiologically linked to another confirmed or 
probable case. During epidemics, diagnosis may be made on the 
basis of history of exposure, incubation period of 2-3 weeks, and 
typical clinical manifestations of fever and parotitis. However, in 
sporadic cases or cases of mumps in a previously vaccinated child, 
laboratory findings such as virus isolation, virus detection, elevation 
of antibody titer, and serum amylase levels are needed to make a 
diagnosis. These criteria apply especially to cases occurring in areas 
with high vaccination rates. 
Virus isolation is performed using the saliva, CSF, or seminal 
fluid collected within the first week of manifestation of symptoms. 
Virus isolation from blood is only possible during the first 3 days of 
illness. Cell culture, RT-PCR, and quantitative real time RT-PCR 
are used to detect the mumps virus. Culture as the sole method 
of diagnosis is not recommended since the cytopathic effect may 
not be evident in some strains of the mumps virus, and cellular 
pathologic changes may also be observed in other diseases that 
need to be differentiated from mumps. RT-PCR is more sensitive 
than cell culture-based methods, and quantitative real time RT-
PCR may be needed to quantify the viral burden. 
Serologic testing may be used to detect IgM, and this method 
is optimal for 7-10 days after symptoms develop. However, this 
method should be used with caution since those with a history of 
mumps or those who have been vaccinated may not demonstrate a 
rise in IgM levels. IgM is not detected after 3 months. IgG is first 
detected 1 week after symptoms manifest, and its titer peaks at 3 
weeks after initial symptoms. However, vaccination may prevent 
such peaks and hence should not be used to exclude the diagnosis 
of mumps. Serologic testing is only informative for mumps 
diagnosis and is of limited predictive value for assessing protecting 
immunity.
Differential diagnosis
The mumps virus is not the only cause of parotitis. Parotitis may 
be caused by EBV, coxsackieviruses, echoviruses, influenza A virus, 
parainfluenza viruses, CMV, HHV-6, etc. Bacterial parotitis is 
characterized by exquisite tenderness of the region, elevated WBC 
count, and pus draining from the Stensen duct. Lymph node 
enlargement is also an important differential diagnosis. Clinical 
findings need to be supplemented with laboratory evidence for 
the diagnosis of mumps, but only 10% of clinically diagnosed 
mumps could be confirmed with laboratory tests
29). A change in 
the diagnosis after serologic testing in a patient suspected to have 
mumps is common in clinical settings
30).
Treatment
There is no specific treatment for mumps. Symptomatic 
treatment such as hydration and alimentation of patients is 
important, and analgesics may be used to treat the severe 
headaches or discomfort caused by parotitis. Antiviral agents are 
inappropriate and not indicated. Supportive treatment should be 
provided in cases with mumps orchitis. Steroid administration 
to patients with mumps orchitis is not recommended because 
steroids may further lower the level of testosterone and increase 
the level of FSH and LH, further aggravating atrophy of the 
testes
31, 32). Postinfectious encephalitis, Guillain- Barré syndrome, 
and idiopathic thrombocytopenic purpura (ITP) are reported as 
autoimmune-related diseases that occur after mumps, and these 
may be treated with IVIG
33-35). 
Prognosis
Symptomatic treatment aids greatly in recovery in most cases. 
Meningoencephalitis has a generally favorable outcome, although 
neurological damage and death can occur. Deafness and sterility 
are rare complications. 
Immunization
Mumps can be prevented by the measles, mumps, rubella 
(MMR) vaccine. The MMR vaccine is widely used worldwide (in 
114 nations) since being licensed in 1967. The first dose is given 
at 12-15 months of age, and the timing of the second dose differs 
among countries. Vaccination of 90% of the population is believed 
to provide herd immunity against the mumps virus
36). As with 
rubella, insufficient childhood vaccination coverage against mumps 
can result in an epidemiological shift in disease incidence to older 
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and complications than that before large-scale immunization was 
introduced. Therefore, mumps vaccination as part of a NIP should 
entail aiming for a high level of disease control.
Viral strains used in the vaccines include Jeryl-Lynn, RIT 4385, 
Urabe Am9, Leningrad-3, and Leningrad-Zagreb strains. There are 
2 types of vaccines currently marketed in Korea. One is Priorix
® 
from GSK; it uses the RIT 4385 strain. The other is MMR
® II 
from Merck; it uses the Jeryl-Lynn strain. The Rubini strain was 
abandoned in routine vaccination programs by the WHO because 
of its low efficacy
37). The Urabe AM9 strain was withdrawn from 
the market because it caused aseptic meningitis in February 2002 
in Korea.
Further, 95% efficacy was reported with the Jeryl-Lynn strain 
in randomized clinical trials
38, 39), but the actual clinical efficacy 
during outbreaks was 61-91%
5). Clinical efficacy during outbreaks 
were acceptable for all strains, except the Rubini strain
5). These 
findings were confirmed not only in Europe and the United 
States but also in Singapore, an Asian country similar to Korea
2). 
The reason for the decrease in clinical efficacy during outbreaks 
is thought to be because of less than optimum herd immunity in 
high-risk settings for exposures, improper storage of the vaccine, 
primary vaccine failure, secondary vaccine failure (waning of 
immunity), heterologous reinfection, confounding factors, 
selections bias, etc. In addition, the level of vaccine effectiveness 
may decrease with time after vaccination
4). In a comparative study, 
the seronegativity rate after 4 years of vaccination was 15% for 
the Urabe strain and 19% for the Jeryl-Lynn strain
40). Mumps 
seropositivity rates and antibody titers peaked shortly after the first 
and second MMR vaccinations and declined rapidly within a year 
after the first dose and at a slower pace after the second dose
41). 
These findings suggest that waning immunity may contribute 
to the occurrence of mumps outbreaks in older vaccinated 
populations.
Post-exposure vaccination is not effective for mumps, although 
vaccination is needed to prevent further infections, and the risk 
does not increase even if vaccination is performed during the 
incubation period. 
We cannot predict who will get mumps during an outbreak. 
No serologic test reliably predicts who is at risk and who is not
42). 
Virus neutralization is the best test available
3), and another 
valuable method is avidity testing for mumps virus-specific IgG
43). 
However, there is no established mumps neutralizing antibody 
titer predictive of protection against infection or disease. The 
presence of mumps IgG is useful for diagnosis of mumps infection, 
not for predicting protection against mumps. Thus, the interval 
between vaccination and exposure is obviously important but is 
not the only factor influencing susceptibility during the recent 
outbreaks of mumps. In the absence of opportunities for antigenic 
boosting, mumps antibody titers will likely continue to wane, 
and greater numbers of individuals who are susceptible to mumps 
may eventually accumulate, resulting in outbreaks that occur less 
frequently but are more severe than previous outbreaks.
It is important to consider that individuals possessing low 
antibody titers or even those lacking measurable antibody titers 
might not necessarily be susceptible to symptomatic mumps virus 
infection because they might be fully protected by cell mediated 
immunity. Cell-mediated immunity has been observed in 
seronegative vaccine recipients even 21 years after vaccination
28).
Conclusion
Despite the high coverage of immunization, mumps outbreaks 
are reported. Various factors are considered to explain this 
observation, such as primary or secondary vaccine failure, 
inadequate levels of vaccination, antigenic differences between 
the outbreak and vaccine strains, increased risk of transmission 
associated with college campuses, inherent limitations in mumps 
protective immunity, and misdiagnosis. To prevent major 
outbreaks, further investigations are needed to identify the optimal 
method of diagnosis, monitor immunization status, and establish 
the most efficient vaccination schedule. However, as observed in 
the Finland outbreak, maintaining a high vaccination rate is the 
most important step toward preventing a mumps outbreak.
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